Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triclosan + tobramycin
- Development stage
- Preclinical
- Lead developer
- TSRLabs
- Modality
- Small Molecules
01
Overview
Triclosan + tobramycin is a small molecule combination drug candidate being developed by TSRLabs for the treatment of cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (NCFB). The combination pairs tobramycin, an aminoglycoside antibiotic that targets bacterial protein synthesis, with triclosan, an antimicrobial compound that inhibits bacterial fatty acid synthesis. Scientific research has shown that triclosan acts as an adjuvant to tobramycin, and together the two compounds synergistically eradicate *Pseudomonas aeruginosa* biofilms—a key driver of chronic lung infections in CF and NCFB patients—achieving bactericidal effects that neither compound alone can replicate.
- Other names
- tobramycin + triclosantriclosan/tobramycin
02
Targets
Bacterial RibosomeInhA
Beyond the preview
Go deeper on triclosan + tobramycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triclosan + tobramycin.